

13th January, 2025

BSE Limited
P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Intimation of Conference Call with Investors/Analysts under the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 ('Listing Regulations')

Dear Sir / Madam,

Pursuant to Regulation 30(6) of the Listing Regulations, please find enclosed herewith the details of the Conference Call with investors/ analysts.

Kindly take this on record.

Thanking you,

Yours truly,
For **Piramal Pharma Limited**

Tanya Sanish
Company Secretary

Encl: a/a

Q3 and 9M FY2025 Earnings Conference Call

Piramal Pharma Limited will be hosting a conference call for investors / analysts on **29th January 2025 from 5:30 PM to 6:15 PM (IST) to discuss its Q3 and 9M FY2025 Results.**

The dial-in details for the call are as under:

Event	Location & Time	Telephone Number
Conference call on 29 th January, 2025	India – 05:30 PM IST	+91 22 6280 1461 / +91 22 7115 8320 (Primary Number)
		1 800 120 1221 (Toll free number)
	USA – 07:00 AM (Eastern Time – New York)	Toll free number 18667462133
	UK – 12:00 PM (London Time)	Toll free number 08081011573
	Singapore – 08:00 PM (Singapore Time)	Toll free number 8001012045
	Hong Kong – 08:00 PM (Hong Kong Time)	Toll free number 800964448
Express Join with Diamond Pass™	Please use this link for prior registration to reduce wait time at the time of joining the call – Click Here	

About Piramal Pharma Ltd:

Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics/bio-therapeutics and vaccine segments. In October 2020, PPL received a 20% strategic growth investment from the Carlyle Group.

For more information, visit: [Piramal Pharma](#) | [LinkedIn](#)

* Includes one facility via PPL's minority investment in Yapan Bio

For Queries:

Gagan Borana

Investor Relations & Enterprise Risk Management

gagan.borana@piramal.com

Piramal Pharma Limited

CIN: L24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India
T: +91 22 3802 3000 / 4000; Email: shareholders.ppl@piramal.com

piramalpharma.com